<DOC>
	<DOCNO>NCT01220271</DOCNO>
	<brief_summary>The purpose trial show proof concept block Transforming Growth Factor-beta signal pathway patient Glioblastoma , clinical benefit . Phase 1b : To determine safe tolerable dose LY2157299 combination radiochemotherapy temozolomide Phase 2 patient glioma eligible receive radiochemotherapy temozolomide ( e.g . newly diagnose malignant glioma World Health Organization Grade III IV ) . Phase 2a : To confirm tolerability evaluate pharmacodynamic effect LY2157299 combination standard radiochemotherapy patient newly diagnose glioblastoma .</brief_summary>
	<brief_title>A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy Patients With Newly Diagnosed Malignant Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients histologically proven , newly diagnose untreated intracranial glioblastoma include low grade glioma evolve glioblastoma receive radiochemotherapy World Health Organization Grade III malignant glioma ( e.g. , Anaplastic Astrocytomas , Anaplastic Oligoastrocytomas , Anaplastic Oligodendroglioma ) ( Phase 1b ) eligible protocol Biopsy resection must perform 6 week prior treatment An Magnetic Resonance Imaging must obtain within 72 hour surgery , preferably within 48 hour Patient must prior cranial radiation therapy Patients must receive prior cytotoxic drug therapy , noncytotoxic drug therapy , experimental drug therapy brain tumor Patients receive Gliadel wafer time original resection exclude Patients must plan begin partial brain radiotherapy within 26 week surgery . Regular fractionate radiotherapy photon ( plan mode possibly imageguided stereotactic deemed necessary ) perform accord discretion investigator Patients must willing forego cytotoxic noncytotoxic drug therapy tumor treat LY2157299 temozolomide All patient must sign informed consent indicate aware investigational nature study Patients must performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Patients must adequate hematologic , hepatic renal function Male female patient reproductive potential must use approved contraceptive method , 6 month discontinuation study treatment Women childbearing potential must negative human chorionic gonadotropin pregnancy test document within 14 day prior treatment Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device approve use drug device ( study drug/device use study ) , concurrently enrol type medical research judge scientifically medically compatible study Have moderate severe cardiac disease define follow : Have presence cardiac disease , include myocardial infarction within 6 month prior study entry , unstable angina pectoris , New York Heart Association ( NYHA ) Class III/IV congestive heart failure , uncontrolled hypertension Have document major electrocardiogram ( ECG ) abnormalities symptomatic medically control Have major abnormality document echocardiography Doppler Have predispose condition consistent development aneurysm ascend aorta aortic stress Are unable swallow tablet capsule Are pregnant breastfeed Have significant medical illness investigator 's opinion adequately control appropriate therapy would compromise patient 's ability tolerate therapy Have history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) , unless complete remission stop therapy disease minimum 3 year ineligible Have active infection would interfere study objective influence study compliance Stereotactic radiosurgery , GammaKnife treatment , brachytherapy allow study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Glioma</keyword>
	<keyword>Glioblastoma</keyword>
</DOC>